Clinical Trial Landscape March 2026 — Phase 3 Activity by Disease Area

Phase 3 landscape by indication

Sorted by active Phase 3 trial count. Phase counts include all active statuses (Recruiting, Active Not Recruiting, Not Yet Recruiting). Click any disease to explore trials on the dashboard.

Disease Area	Phase 3	Phase 2	Phase 1	Total Active	Sponsors
Rheumatoid Arthritis	606	1400	704	7784	2826
Acute Lymphoblastic Leukemia (ALL)	292	735	322	1988	829
Spinal Muscular Atrophy	203	482	205	1193	504
Breast Cancer	159	364	164	1268	517
Lung Cancer	151	370	176	1018	440
Small Cell Lung Cancer	126	310	137	700	343
Non-Small Cell Lung Cancer (NSCLC)	114	262	110	605	311
Multiple Sclerosis	107	170	127	972	519
Leukemia	69	314	202	747	257
Obesity	66	70	62	632	353
Prostate Cancer	64	215	97	676	304
Colorectal Cancer	55	201	104	576	347
Multiple Myeloma	55	141	89	370	148
Diabetes	53	67	43	755	446
Stroke	44	33	10	576	377
Bladder Cancer	41	96	57	284	152
Lupus (SLE)	37	57	69	536	352
Chronic Kidney Disease	37	22	21	267	180
Alzheimer's Disease	37	44	24	227	148
Ovarian Cancer	36	114	82	313	176
Hypertension	29	47	23	389	258
Depression	27	56	21	541	347
Heart Failure	27	33	10	365	251
Psoriasis	27	8	7	90	61
Heart Disease	26	25	5	342	209
Sarcoma	26	138	81	328	141
Acute Myeloid Leukemia (AML)	26	123	120	315	141
Liver Cancer	26	95	50	285	183
Melanoma	25	128	64	292	156
Chronic Lymphocytic Leukemia (CLL)	25	70	25	158	72
Gastric Cancer	24	68	42	201	133
Myasthenia Gravis	24	9	5	61	37
Type 2 Diabetes	23	17	15	255	188
Asthma	23	38	7	189	127
Pancreatic Cancer	22	114	83	328	209
Hemophilia	22	6	5	65	31
Crohn's Disease	20	25	7	135	82
Ulcerative Colitis	20	35	8	129	84
Migraine	20	7	2	100	58
Head & Neck Cancer	19	95	62	243	155
DLBCL	18	52	31	124	75
Endometrial Cancer	17	57	51	176	107
Kidney Cancer	17	73	32	173	102
COPD	16	25	5	171	117
Dementia	16	20	6	162	121
Schizophrenia	16	21	6	138	106
Psoriatic Arthritis	15	4	5	45	31
Glioblastoma	14	79	64	198	122
Epilepsy	14	7	9	116	71
Atopic Dermatitis	14	34	16	114	81

The 10 most active Phase 3 indications

These disease areas currently have the largest Phase 3 trial pipelines on ClinicalTrials.gov as of March 2026:

1. Rheumatoid Arthritis — 606 Phase 3 trials, 2826 sponsors
2. Acute Lymphoblastic Leukemia (ALL) — 292 Phase 3 trials, 829 sponsors
3. Spinal Muscular Atrophy — 203 Phase 3 trials, 504 sponsors
4. Breast Cancer — 159 Phase 3 trials, 517 sponsors
5. Lung Cancer — 151 Phase 3 trials, 440 sponsors
6. Small Cell Lung Cancer — 126 Phase 3 trials, 343 sponsors
7. Non-Small Cell Lung Cancer (NSCLC) — 114 Phase 3 trials, 311 sponsors
8. Multiple Sclerosis — 107 Phase 3 trials, 519 sponsors
9. Leukemia — 69 Phase 3 trials, 257 sponsors
10. Obesity — 66 Phase 3 trials, 353 sponsors

What this data tells you

Phase 3 trial activity is a leading indicator of where pharmaceutical investment is concentrated. A high Phase 3 count means:

• Competitive intensity: Multiple sponsors are betting on a mechanism or indication with expensive late-stage programs
• Near-term approvals: Phase 3 programs typically read out in 2–5 years, signaling the pipeline of future approvals
• Market growth: Phase 3 enrollment is expensive — sponsors invest only in areas with commercial potential
• Clinical site demand: Disease areas with many Phase 3 trials have high site competition and enrollment challenges

How to use this data

For biotech BD teams

Use Phase 3 density to identify spaces that are crowded (differentiation required) vs. spaces with limited competition (first-mover opportunity). A disease area with 20+ Phase 3 trials from different sponsors typically indicates a validated mechanism with commercial precedent — but also requires differentiation on patient population, endpoint, or safety profile.

For healthcare analysts and investors

Phase 3 trial count correlates with pipeline value. Disease areas with high Phase 3 activity have computable near-term catalyst density — the higher the count, the more readout events to model. DataLookout alerts you when trial statuses change, enrollment updates, or sponsors enter new indications.

For clinical operations teams

Disease areas with high Phase 3 counts have the most site competition. Sites enrolling in "hot" indications like Rheumatoid Arthritis, Multiple Myeloma, or NSCLC are simultaneously competing for subjects across 50–100+ active trials. This drives up screen failure rates and slows enrollment — a key factor in site selection and timeline modeling.

Methodology

DataLookout collects clinical trial data daily from the ClinicalTrials.gov API. Active trial counts include studies with status: Recruiting, Active Not Recruiting, or Not Yet Recruiting. Phase counts are based on the phases field in each trial record. Disease area classification uses a curated disease map that groups synonymous condition names (e.g., "non-small cell lung cancer", "NSCLC", "lung adenocarcinoma" → Lung Cancer) to avoid double-counting. Data is refreshed daily; this page updates weekly as part of the scheduled site deployment.

Data sourced from ClinicalTrials.gov. Last updated: March 29, 2026. DataLookout monitors ClinicalTrials.gov daily and detects changes in trial status, enrollment, endpoints, and sponsor activity.